Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Non-Current Deffered Revenue (2016 - 2025)

Oramed Pharmaceuticals filings provide 10 years of Non-Current Deffered Revenue readings, the most recent being $1.3 million for Q4 2025.

  • Quarterly Non-Current Deffered Revenue fell 68.27% to $1.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.3 million through Dec 2025, down 68.27% year-over-year, with the annual reading at $1.3 million for FY2025, 68.27% down from the prior year.
  • Non-Current Deffered Revenue hit $1.3 million in Q4 2025 for Oramed Pharmaceuticals, down from $1.5 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $5.6 million in Q1 2021 and bottomed at $1.3 million in Q4 2025.
  • Average Non-Current Deffered Revenue over 5 years is $3.5 million, with a median of $4.0 million recorded in 2022.
  • The largest annual shift saw Non-Current Deffered Revenue soared 100.0% in 2023 before it tumbled 68.27% in 2025.
  • Oramed Pharmaceuticals' Non-Current Deffered Revenue stood at $3.6 million in 2021, then rose by 12.04% to $4.0 million in 2022, then changed by 0.0% to $4.0 million in 2023, then changed by 0.0% to $4.0 million in 2024, then tumbled by 68.27% to $1.3 million in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Non-Current Deffered Revenue are $1.3 million (Q4 2025), $1.5 million (Q3 2025), and $2.0 million (Q2 2025).